AUG 12, 2021 8:05 AM PDT

Promising Drug Target Identified for Deadly Ovarian Cancer

WRITTEN BY: Annie Lennon

Scientists at the University of Alabama at Birmingham have identified a gene called DOT1L for its role in progressing the severity of ovarian cancer. They also found that inhibiting DOT1L enzymes may offer a new therapeutic approach to the disease. The results were published in Oncogenesis.

Ovarian cancer is one of the most deadly forms of cancer. The five-year survival rate for patients with advanced forms of the disease is between 10 and 30%. While the condition can occur at any age, it is most common among women aged 50 to 60 years old. 

Earlier research has shown that a gene known as DOT1L is overexpressed in many cancer types. In the present research, scientists sought to see whether the gene has a role in ovarian cancer too, and whether it could be used as a drug target. 

To do so, they examined publically available datasets from patients with ovarian cancer. They found that levels of DOT1L mRNA were significantly higher in patient-derived samples of ovarian cancer than in control tissues. 

They also found that patients with ovarian tumors and high DOT1L expression had shorter progression-free survival (PFS) and overall survival (OS) than patients with low DOT1L expression. 

While patients with low DOT1L expression had a median PFS of 19 months and a median OS of 45.73 months, those with high DOT1L expression had an average PFS of 13.1 months and an OS of 39.87 months. 

Clinical trials have found that EPZ-5676, a DOT1L inhibitor, is effective in treating MLL-rearranged leukemia. The researchers thus conducted experiments to see how the drug interacted with ovarian cancer cells. 

They found that it was able to block ovarian cancer tumor growth both in cellular models and in a mouse xenograft model. 

Upon examination of their cell models, the researchers found that DOT1L inhibition reduced levels of essential biosynthetic metabolites in ovarian cancer cells. It also increased apoptotic cell death for ovarian cancer cells by upregulating genes involved in programmed cell death. In some cell line tested, DOT1L inhibitor additionally upregulated the expression of ligands for natural killer cells. 

"Our results suggest that DOT1L might be a pharmacologically tractable drug target for ovarian cancer therapy," said Romi Gupta, lead author of the study. "It will also be useful in combination with other immunotherapeutic agents to further enhance their effectiveness in treating ovarian cancer."

 

Sources: OncogenesisMayo ClinicScience Daily

About the Author
  • Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
JUN 07, 2021
Cell & Molecular Biology
Overcoming Challenges to Detect Apoptosis in 3D Cell Structures
JUN 07, 2021
Overcoming Challenges to Detect Apoptosis in 3D Cell Structures
Researchers are increasingly relying on cells grown in three-dimensional (3D) structures to help answer their research q ...
JUL 07, 2021
Cancer
Chemotherapy Disrupts Gut Bacteria in Cancer Patients
JUL 07, 2021
Chemotherapy Disrupts Gut Bacteria in Cancer Patients
Researchers from Australia have found that the conventional chemotherapy used to treat various cancers disrupts the comp ...
JUL 13, 2021
Clinical & Molecular DX
Friend or Foe? New Cancer-Tracking Pen Guides Surgeons.
JUL 13, 2021
Friend or Foe? New Cancer-Tracking Pen Guides Surgeons.
Researchers have developed the first diagnostic “pen” that acts as a guide for surgeons, helping them distin ...
JUL 16, 2021
Cancer
Exercise Slows Growth of Bowel Cancer Cells
JUL 16, 2021
Exercise Slows Growth of Bowel Cancer Cells
Exercise releases molecules into the bloodstream that reduce the growth of bowel cancer cells, say researchers from the ...
SEP 06, 2021
Cancer
A New Biomarker to Personalize Breast Cancer Therapy
SEP 06, 2021
A New Biomarker to Personalize Breast Cancer Therapy
The American Cancer Society estimates that over 280,000 women in the United States will be diagnosed with breast cancer ...
SEP 16, 2021
Technology
Scientists Create Tiny Replicas Of The Pancreas To Study New Drugs
SEP 16, 2021
Scientists Create Tiny Replicas Of The Pancreas To Study New Drugs
Pancreatic cancer it’s often hard to diagnose in its early stages, resulting in patients having more advanced canc ...
Loading Comments...